SMT201500028B - N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici - Google Patents

N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici

Info

Publication number
SMT201500028B
SMT201500028B SM201500028T SM201500028T SMT201500028B SM T201500028 B SMT201500028 B SM T201500028B SM 201500028 T SM201500028 T SM 201500028T SM 201500028 T SM201500028 T SM 201500028T SM T201500028 B SMT201500028 B SM T201500028B
Authority
SM
San Marino
Prior art keywords
pyridinyl
pyrimidinyl
thienyl
oxy
phenyl
Prior art date
Application number
SM201500028T
Other languages
English (en)
Italian (it)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500028(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SMT201500028B publication Critical patent/SMT201500028B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500028T 2009-09-11 2015-02-09 N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici SMT201500028B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
SMT201500028B true SMT201500028B (it) 2015-03-05

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500028T SMT201500028B (it) 2009-09-11 2015-02-09 N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici

Country Status (34)

Country Link
US (1) US20120028917A1 (https=)
EP (2) EP2475368B1 (https=)
JP (1) JP5851403B2 (https=)
KR (1) KR20120082896A (https=)
CN (1) CN102869361A (https=)
AU (1) AU2010292225C1 (https=)
BR (1) BR112012008325A2 (https=)
CA (1) CA2773838C (https=)
CL (1) CL2012000640A1 (https=)
CR (1) CR20120171A (https=)
DK (1) DK2475368T3 (https=)
EA (1) EA020526B1 (https=)
ES (1) ES2528485T3 (https=)
HK (1) HK1205457A1 (https=)
HR (1) HRP20150104T1 (https=)
HU (1) HUE024568T2 (https=)
IL (1) IL218569A0 (https=)
MA (1) MA33658B1 (https=)
ME (1) ME02048B (https=)
MX (1) MX2012003041A (https=)
NZ (1) NZ598758A (https=)
PE (1) PE20120895A1 (https=)
PH (1) PH12012500504A1 (https=)
PL (1) PL2475368T3 (https=)
PT (1) PT2475368E (https=)
RS (1) RS53807B1 (https=)
SG (1) SG179102A1 (https=)
SI (1) SI2475368T1 (https=)
SM (1) SMT201500028B (https=)
TN (1) TN2012000110A1 (https=)
TW (1) TW201121956A (https=)
UA (1) UA107675C2 (https=)
WO (1) WO2011031842A1 (https=)
ZA (1) ZA201202472B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518053A (ja) * 2012-05-31 2015-06-25 アムジエン・インコーポレーテツド 癌の治療のためのamg900の使用
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
HRP20220718T1 (hr) 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
US10053452B2 (en) 2013-12-03 2018-08-21 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders
CN109313197A (zh) * 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
AU2007208351C1 (en) * 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination

Also Published As

Publication number Publication date
AU2010292225C1 (en) 2013-06-27
EP2818170B1 (en) 2018-12-05
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
EA201270383A1 (ru) 2013-04-30
CA2773838A1 (en) 2011-03-17
IL218569A0 (en) 2012-05-31
RS53807B1 (sr) 2015-06-30
JP5851403B2 (ja) 2016-02-03
PE20120895A1 (es) 2012-08-19
CR20120171A (es) 2012-08-09
PL2475368T3 (pl) 2015-05-29
TN2012000110A1 (en) 2013-09-19
TW201121956A (en) 2011-07-01
NZ598758A (en) 2013-12-20
WO2011031842A1 (en) 2011-03-17
HRP20150104T1 (xx) 2015-03-13
US20120028917A1 (en) 2012-02-02
MA33658B1 (fr) 2012-10-01
MX2012003041A (es) 2012-06-27
CA2773838C (en) 2016-05-31
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
EP2475368B1 (en) 2014-12-17
HK1173655A1 (en) 2013-05-24
EA020526B1 (ru) 2014-11-28
ZA201202472B (en) 2012-12-27
AU2010292225A1 (en) 2012-04-12
DK2475368T3 (en) 2015-03-09
PT2475368E (pt) 2015-02-10
ME02048B (me) 2015-05-20
KR20120082896A (ko) 2012-07-24
HK1205457A1 (en) 2015-12-18
HUE024568T2 (hu) 2016-02-29
ES2528485T3 (es) 2015-02-10
CN102869361A (zh) 2013-01-09
PH12012500504A1 (en) 2015-04-29
SG179102A1 (en) 2012-04-27
UA107675C2 (xx) 2015-02-10
CL2012000640A1 (es) 2012-09-21
BR112012008325A2 (pt) 2017-08-29
AU2010292225B2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
SMT201500028B (it) N-(4-((3-(2-ammino-4-pirimidinil)-2-piridinil)ossi)fenil)-4-(4-metil-2-tienil)-trattamento di un cancro resistente ad agenti antimitotici
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
DK2191831T3 (da) Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion
DK2318396T5 (da) Krystalform af posaconazol
DK2064189T3 (da) Polymorfe former af 4-[3-(4-cyklopropancarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phathalazin-1-on
SMT201400010B (it) Purificazione di 1-[2-(2,4-dimetilfenilsolfanil)fenilÜpiperazin a
PL2503993T3 (pl) Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1H-pirazol-3-ilo]oksy]etylo]morfoliny
DK2086642T3 (da) Dnase til behandling af subfertilitet hos mænd
EP2114785A4 (en) LID FOR A TOBACCO CAN
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
EP2446315A4 (en) MODULAR MICROSCOPE CONSTRUCTION
SMT201600031B (it) Composti eterociclici di fenossimetile
EP2735414A4 (en) CUT PROCESSING MECHANISM
UY33147A (es) Carboxamidas 2-(ariloxi biciclicas)fungicidas
DK2175849T3 (da) Behandling af melanomer
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
ATE514685T1 (de) Herbizid wirksame 4- (3-aminobenzoyl) -5- cyclopropylisoxazole
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
IT1395453B1 (it) Assieme placca/controplacca di comando di una cassetta di risciacquo
DK2516418T3 (da) Pro-drugs af [4[4-(5-aminomethyl-2-fluor-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanoner og syntese deraf
HK1176863A (en) Hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine
UA17116S (uk) Набір офісних меблів
UA17976S (uk) Комплект одягу для офіціанта
UA17977S (uk) Комплект одягу для офіціанта